West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
WNVis a positive single-stranded RNA flavivirus of ab
out 11 kb. It primarily infe...
Skin Rash Actually Signifies Better Outcomes for Pancreatic and
Lung Cancer Patients
PHILADELPHIA, July 3, 2007-- – The appearance of arash in cancer patients treated with erlotinib (Tarceva) isstrongly associated with longer survival, according to researchersfrom the drug’s developer, OSI Pharmaceuticals, Inc. This isnot the first time that rash has been associated with a survivaladvantage with EGFR inhibitors – a class of drugs whichincludes erlotinib...
Advanced Cell Technology Develops First Human Embryonic Stem Cell
Line without Destroying an Embryo
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun 21, 2007 - Advanced CellTechnology, Inc. (OTCBB: ACTC) has successfully produced a humanembryonic stem cell (hESC) line with
out destroying an embryo at itslab in Worcester, Massachusetts. This development was announced byRobert Lanza, M.D., V.P. of Research and Scientific Development ofAdvanced Cell Technology (ACT) on Tuesday at the fifth annualmeeting...
MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating
MacroVascular Outcomes Presented at the American Diabetes
Association 67th Scientific Sessions
Data from the PROactive and CHICAGO studies of ACTOS(R)(pioglitazone HCl) will be presented in poster format at the 67thScientific Sessions of the American Diabetes Association inChicago: -- Hospitalizations for serious adverse events in high-risk type 2 diabetes patients treated with pioglitazone for 3...
Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07
Teleconference to Answer Questions About TA-65, Their Telomerase
Activator With Proven Age Management Benefits
NEW YORK, June 15, 2007 /PRNewswire/ -- Telomerase ActivationSciences, Inc. (T.A. Sciences) recently announced the results ofthe Pivotal 2005 Anti-Aging Trial of TA-65, the first human trialever to show demonstrated, measurable and positive anti-agingbenefits from a Telomerase Activator. Statistically significantresults were found in those taking TA-65 across several keyconditions of agi...
Women Well-Informed About Breast Cancer, Yet Lacking Knowledge
About Current Treatments, New Survey Finds
-- CancerCare offers five questions to help womenlearn ab
out breast cancer therapy advances -- NEW YORK, June 12, 2007 – According to a newGfK Roper Public Affairs survey sponsored by CancerCare, a nationalnonprofit cancer support organization, while the majority (76percent) of women surveyed said they know at least a fair amountab
out breast cancer...
International Movement Disorder Specialists Receive New Information
About the Use of Once-Daily Azilect in the Treatment of Parkinson's
Disease
Results presented at the Movement Disorder Society's 11thInternational Congress in Istanbul, Turkey KANSAS CITY, Mo., June 08, 2007 /PRNewswire-FirstCall/ -- Newinformation on the use of AZILECT(R) (rasagiline tablets) for thetreatment of Parkinson's disease (PD) was reported this week at TheMovement Disorder Society's congress in Istanbul, Turkey.Once-daily AZILECT was approved by the FD...
Savient Pharmaceuticals Announces Acceptance of Two Gout-Related
Abstracts for Poster Presentation at the European League Against
Rheumatism (EULAR) 2007 Annual Congress
EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Jun 6, 2007 - SavientPharmaceuticals, Inc. (NASDAQ: SVNT) announced today that twoabstracts exploring Phase 2 Puricase(R) (PEG-uricase) data andquality of life in treatment-failure g
out patients will bepresented at the European League Against Rheumatism (EULAR) 2007Annual Congress taking place June 13 - 16th in Barcelona, Spain.Puricase is a PEGylated...
New Study Suggests Better Patient Outcomes with CYPHER
Sirolimus-Eluting Coronary Stent than with Taxus Stent in
Real-World Clinical Settings
Registry Analysis Published in Journal Heart Finds Taxus Stent,Implantation of Multiple Stents and Small Vessel Size To BeIndependent Predictors of Need for Another Procedure MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX NewsNetwork/ -- An analysis of data from the Western Denmark HeartRegistry found that patients who received the CYPHER(R)Sirolimus-eluting Coronary...
Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA
Vaccine Performance; Yields Antibody Responses Comparable to
Electroporation Without Tolerability Issues
MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patentedVaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody responses than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, electro...
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes
for Moderate-Release Paclitaxel-Eluting Stent at Four Years
Trial results report no new stent thrombosis after two years inhigh-risk patient population NATICK, Mass., and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced four-year follow-up data from its TAXUS VI clinicaltrial. The data demonstrated that the safety and efficacy benefitsassociated with a moderate-release formulation of the TAXUS(R)...
Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to
Bypass Surgery and Better Outcomes Than Bare Metal Stents in
Subgroup Analysis of Diabetic Patients With Multivessel Coronary
Disease
BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- A three-yearfollow-up subset analysis presented today as a late-breakingclinical trial at EuroPCR 2007 showed that the CYPHER(R)Sirolimus-eluting Coronary Stent had results comparable to coronaryartery bypass grafting (CABG or bypass surgery) and better
outcomesthan bare metal stents (BMS) in diabetic patients with blockages intw...
New Study Results Provide Additional Data about Short- and
Long-Term Use of Desvenlafaxine Succinate in the Treatment of
Adults with Major Depressive Disorder
- Data Presented at 2007 APA Meeting - COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ -- Datafrom four new studies examining safety and efficacy ofdesvenlafaxine succinate, a serotonin-norepinephrine reuptakeinhibitor (SNRI) being studied as a potential treatment for adultswith major depressive disorder (MDD), were presented today at the2007 American Psychiatric Association annual...
FDA Proposes New Warnings About Suicidal Thinking, Behavior in
Young Adults Who Take Antidepressant Medications
ROCKVILLE, Md., May 2, 2007-The U.S. Food and DrugAdministration (FDA) today proposed that makers of allantidepressant medications update the existing black box warning ontheir products' labeling to include warnings ab
out increased risksof suicidal thinking and behavior, known as suicidality, in youngadults ages 18 to 24 during initial treatment (generally the firstone to two months).</p...
Ad hoc: Interim report about clinical trial of BF-200 ALA in
actinic keratosis
LEVERKUSEN, Germany, 30 April 2007 - Biofrontera AG announcedthat an interim report regarding the clinical study of BF-200 ALAin actinic keratosis was received today from an independent reviewcommittee. The objectives of the study are to investigate theefficacy and safety of several doses of BF-200 ALA in photodynamictherapy. The comments received today refer to the clinical resultseight...
Doctors Outraged Over Growth Hormone Controversy
Two anti-aging preventative medicine doctors say they are
outragedover recent media coverage ab
out their advocacy of prescribinghuman growth hormone to treat a hormone deficiency often associatedwith aging. DAYTONA BEACH, Fla., April 27, 2007 /PRNewswire/ -- The adultuse of human growth hormone (HGH) was at the center of a recent NewYork Times article ab
out the founders of the American Ac...
Cortex Area Thinner in Youth with Alzheimers-Related Gene
BETHESDA, Md., April 23, 2007--A part of the brain firstaffected by Alzheimers disease (<a target="_blank" href="http://www.nia.nih.gov/Alzheimers/">http://www.nia.nih.gov/Alzheimers/ )is thinner in y
outh with a risk gene for the disorder, a brainimaging study by researchers at the National Institute of MentalHealth (NIMH), one of the National Institutes of Health (NIH), hasfound. A t...
Prospective Model Outlined Potential Time and Cost Savings of
Once-Monthly Anemia Treatment
DALLAS, Texas and NUTLEY, N.J., April 23, 2007 /PRNewswire/ --An activity-based cost analysis demonstrated that if a renal anemiatreatment administered once every four weeks replaced thrice weeklyadministration of epoetin alfa, hemodialysis centers may save anestimated 802 nursing hours and more than $44,000 per year per 100patients. These data, from a multi-center prospective analysis of...
Addex Achieves Statistically Significant Outcome in Phase IIa
Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
GENEVA, April 17, 2007 /PRNewswire/ -- Addex Pharmaceuticalsannounced today the successful completion of a Phase IIa proof ofconcept trial with its lead compound ADX10059 in patients withgastro-esophageal reflux disease (GERD), a highly prevalentcondition with a significant unmet medical need. The study achievedits primary objective, the control of 24-hour esophageal pH, withstatistical...
Data Analyses Outline Efficacy and Safety of Mircera for the
Treatment of Renal Anemia Associated With Chronic Kidney Disease
ORLANDO, Fla. and NUTLEY, N.J., April 12, 2007/PRNewswire-FirstCall/ -- Data analyses from the largest initialregistration clinical trial program ever undertaken in the renalanemia arena provide efficacy and safety information on theinvestigational anemia therapy MIRCERA(TM) for the treatment ofrenal anemia associated with chronic kidney disease (CKD) inpatients on dialysis and not on di...
Southern Research Institute to Present at the 2007 American
Association For Cancer Research Annual Meeting
BIRMINGHAM, Ala., April 03, 2007 /PRNewswire/ -- S
outhernResearch Institute, a not-for-profit organization that conductsbasic and applied research in the areas of preclinical drugdiscovery and drug development today announced that its scientistswill be delivering one oral presentation and 10 posterpresentations at the 2007 American Association for Cancer Research(AACR) Annual Meeting, Ap...
Six Important Things to Know About Preventing Hospital Infections
Infection Control Professional Offers Patient Tips to Guard AgainstHospital Infections KANSAS CITY, Kan., April 02, 2007 /PRNewswire/ -- Hospitalinfections are among the top ten leading causes of death in theUnited States, according to the Centers for Disease Control. Thereare countless stories ab
out patients who go into hospitals withminor conditions and leave under much graver circumsta...
Inimex Product Candidate is First Immune Defense Regulator to Cure
Infections Without Causing Harmful Inflammation
Novel Approach to Address Growing Problem of Antibiotic ResistancePublished in Nature Biotechnology VANCOUVER, British Columbia, March 26, 2007 /PRNewswire/ --Inimex Pharmaceuticals Inc.'s product candidate IDR-1 is the firstimmune system trigger to cure infections with
out causing harmfulinflammation, according to a paper published in the April 2007issue of Nature Biotechnology. Th...
The American Liver Foundation Urges Cautious Optimism about CDC
Report on Declining Acute Hepatitis Infection Rates
Focus Must Remain on the Millions Still Suffering from ChronicHepatitis B and C NEW YORK, March 21, 2007 /PRNewswire/ -- The Centers for DiseaseControl and Prevention (CDC) has reported that significant declinein the rates of new acute hepatitis infections in the United Statesin the last 10 years, reflecting the success of hepatitis A and Bvaccination programs. The American Liver Foundati...
Researchers Find Surprising Pattern of Influenza Spread in South
America and Tropics
BETHESDA, Md., March 20, 2007--Researchers studying influenzatransmission patterns in the S
outhern Hemisphere and in tropicalareas, specifically Brazil, uncovered the unexpected finding thateach season influenza travels from low populated regions near theequator to the more populated centers. Their work, funded by theFogarty International Center (NIH), part of the National Institutesof H...
REACH Registry Demonstrates That Multiple Arterial Disease
Locations Sharply Increase the Risk of Major CV Events in
Outpatients With Atherothrombosis
- The Reduction of Atherothrombosis for Continued Health(REACH) PARIS, March 20, 2007 /PRNewswire/ --The REACH Registry 1-yearresults paper published today in the Journal of the AmericanMedical Association (JAMA) show that
outpatients withatherothrombosis have a surprisingly high risk of death or majorcardiovascular illness, especially if more than...
Inflazyme Announces Outcome of Review of Phase 2b Asthma Study:
Potential Mitigating Factors Identified which Prevent Clear
Interpretation of Results
RICHMOND, British Columbia, March 12, 2007--InflazymePharmaceuticals Ltd. (TSX: IZP). As announced on January 29, 2007,the preliminary results of the Phase 2b CAPSICS study withIPL512,602 showed no statistical or clinical difference betweenpatients who received drug or placebo. However, the placeboresponse was surprisingly large and consistent across a number ofthe end-points, which prom...
POZEN Announces Positive Outcome for PA 325 Proof of Concept Study
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar 6, 2007 - POZEN Inc.(NASDAQ: POZN), today announced top-line results of its "SaferAspirin" PA 325 proof-of-concept study conducted during the fourthquarter of 2006. PA 325 is a patented formulation of 325mg ofaspirin surrounded by a 20mg coating of an immediate releaseformulation of a proton pump inhibitor. The PA 325, 28 day study, involved two gro...
Pozen Announces Positive Outcome for PA 325
Chapel Hill, N.C., March 6, 2007-Pozen Inc. (NASDAQ: POZN),today announced top-line results of its "Safer Aspirin" PA 325proof-of-concept study conducted during the fourth quarter of 2006.PA 325 is a patented formulation of 325mg of aspirin surrounded bya 20mg coating of an immediate release formulation of a proton pumpinhibitor. The PA 325, 28 day study, involved two groups of 40...